Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 650846, 9 pages
http://dx.doi.org/10.1155/2015/650846
Review Article

Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward

1Department of Medical Oncology, University of Antwerp, 2650 Antwerp, Belgium
2Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK
3Department of Surgical and Oncology Sciences, University of Palermo, 90127 Palermo, Italy
4Department of Radiation Oncology, B.O.C. Oncology Centre, 2006 Nicosia, Cyprus
5Department of Medical Oncology, B.O.C. Oncology Centre, 2006 Nicosia, Cyprus

Received 9 March 2015; Revised 10 May 2015; Accepted 12 May 2015

Academic Editor: Vikram Kate

Copyright © 2015 Konstantinos Papadimitriou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Lau, A. Le, and H. B. El-Serag, “Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival,” The American Journal of Gastroenterology, vol. 101, no. 11, pp. 2485–2492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, F. Bray, D. M. Parkin et al., Gobocan 2000: Cancer Incidence and Mortality Worldwide, IARC Cancer Bases no. 5, IARC Press, Lyon, France, 2001.
  3. American Cancer Society, Cancer Facts & Figures, American Cancer Society, 2008.
  4. D. Cunningham, W. H. Allum, S. P. Stenning et al., “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” The New England Journal of Medicine, vol. 355, no. 1, pp. 11–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Hundahl, J. L. Phillips, and H. R. Menck, “The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the different diseas hypothesis,” Cancer, vol. 88, no. 4, pp. 921–932, 2000. View at Google Scholar · View at Scopus
  6. J. Hermans, J. J. Bonenkamp, M. C. Boon et al., “Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials,” Journal of Clinical Oncology, vol. 11, no. 8, pp. 1441–1447, 1993. View at Google Scholar · View at Scopus
  7. L. L. Gunderson, J. H. Donohue, P. A. Burch et al., Clinical Oncology, Churchill Livingstone, New York, NY, USA, 1995.
  8. C. C. Earle and J. A. Maroun, “Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials,” European Journal of Cancer, vol. 35, no. 7, pp. 1059–1064, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. Negative randomized trials of surgery with and without adjuvant combination chemotherapy in resected gastric cancer, http://www.uptodate.com.
  10. X. Paoletti, K. Oba, T. Burzykowski et al., “Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis,” Journal of the American Medical Association, vol. 303, no. 17, pp. 1729–1737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y.-J. Bang, Y.-W. Kim, H.-K. Yang et al., “Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial,” The Lancet, vol. 379, no. 9813, pp. 315–321, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Sasako, T. Kinoshita, H. Furukawa et al., “Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study),” Annals of Oncology, vol. 21, supplement 8, pp. viii225–viii249, 2010. View at Google Scholar
  13. V. Boige, J. Pignon, B. Saint-Aubert et al., “Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial,” Journal of Clinical Oncology, vol. 25, abstract 200s, 2007. View at Google Scholar
  14. C. Schuhmacher, S. Gretschel, F. Lordick et al., “Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954,” Journal of Clinical Oncology, vol. 28, no. 35, pp. 5210–5218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Nio, M. Koike, H. Omori et al., “A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer—a single institute study,” Anticancer Research, vol. 24, no. 3, pp. 1879–1887, 2004. View at Google Scholar · View at Scopus
  16. M. Ychou, V. Boige, J.-P. Pignon et al., “Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial,” Journal of Clinical Oncology, vol. 29, no. 13, pp. 1715–1721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. Macdonald, S. R. Smalley, J. Benedetti et al., “Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction,” The New England Journal of Medicine, vol. 345, no. 10, pp. 725–730, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. G. Bunt, J. Hermans, V. T. H. B. M. Smit, C. J. H. Van De Velde, G. J. Fleuren, and J. A. Bruijn, “Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western Countries,” Journal of Clinical Oncology, vol. 13, no. 1, pp. 19–25, 1995. View at Google Scholar · View at Scopus
  19. A. Ohtsu, S. Yoshida, and N. Saijo, “Disparities in gastric cancer chemotherapy between the east and west,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2188–2196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Macdonald, “Gastric cancer: Nagoya is not New York,” Journal of Clinical Oncology, vol. 29, no. 33, pp. 4348–4350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Yu, R. Yu, W. Zhu, Y. Song, and T. Li, “Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 2, pp. 255–259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. H. Kim, S. R. Park, K. W. Ryu et al., “Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection,” International Journal of Radiation Oncology Biology Physics, vol. 84, no. 5, pp. e585–e592, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. W.-G. Zhu, D.-F. Xua, J. Pu et al., “A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection,” Radiotherapy and Oncology, vol. 104, no. 3, pp. 361–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H.-C. Kwon, M. C. Kim, K. H. Kim et al., “Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection,” Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 4, pp. 278–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Lee, D. H. Lim, S. Kim et al., “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 268–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Ohri, M. K. Garg, S. Aparo et al., “Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis,” International Journal of Radiation Oncology Biology Physics, vol. 86, no. 2, pp. 330–335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Landry, J. E. Tepper, W. C. Wood, E. O. Moulton, F. Koerner, and J. Sullinger, “Patterns of failure following curative resection of gastric carcinoma,” International Journal of Radiation Oncology, Biology, Physics, vol. 19, no. 6, pp. 1357–1362, 1990. View at Publisher · View at Google Scholar · View at Scopus
  28. L. L. Gunderson and H. Sosin, “Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy,” International Journal of Radiation Oncology Biology Physics, vol. 8, no. 1, pp. 1–11, 1982. View at Publisher · View at Google Scholar · View at Scopus
  29. C. G. Moertel, D. S. Childs, J. R. O'Fallon, M. A. Holbrook, A. J. Schutt, and R. J. Reitemeier, “Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma,” Journal of Clinical Oncology, vol. 2, no. 11, pp. 1249–1254, 1984. View at Google Scholar · View at Scopus
  30. D. M. Dent, I. D. Werner, B. Novis, P. Cheverton, and P. Brice, “Prospective randomized trial of combined oncological therapy for gastric carcinoma,” Cancer, vol. 44, no. 2, pp. 385–391, 1979. View at Publisher · View at Google Scholar · View at Scopus
  31. C. G. Moertel, D. S. Childs Jr., R. J. Reitemeier, M. Y. Colby Jr., and M. A. Holbrook, “Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer,” The Lancet, vol. 2, no. 7626, pp. 865–867, 1969. View at Google Scholar · View at Scopus
  32. P. S. Schein, D. M. Stablein, and H. W. Bruckner, “A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma,” Cancer, vol. 49, no. 9, pp. 1771–1777, 1982. View at Google Scholar · View at Scopus
  33. K. Ng, J. A. Meyerhardt, and C. S. Fuchs, “Adjuvant and neoadjuvant approaches in gastric cancer,” Cancer Journal, vol. 13, no. 3, pp. 168–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Ajani, P. F. Mansfield, N. Janjan et al., “Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2774–2780, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. A. Ajani, K. Winter, G. S. Okawara et al., “Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3953–3958, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. R. Smalley, J. K. Benedetti, D. G. Haller et al., “Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection,” Journal of Clinical Oncology, vol. 30, no. 19, pp. 2327–2333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Papadimitriou, V. Vassiliou, P. Kountourakis, P. Polyviou, D. Andreopoulos, and D. Papamichael, “Adjuvant chemoradiotherapy (CRT) for high-risk gastric cancer (GC) patients: single-center experience using infusional 5-fluorouracil (5FU) and radiotherapy (RT),” Medical Oncology, vol. 29, no. 4, pp. 2716–2717, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. S. Macdonald, J. Benedetti, S. R. Smalley et al., “Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008),” Journal of Clinical Oncology, vol. 27, no. 15s, 2009, Abstract no. 4515. View at Google Scholar
  39. S. Kim, D. H. Lim, J. Lee et al., “An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach,” International Journal of Radiation Oncology, Biology, Physics, vol. 63, no. 5, pp. 1279–1285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Fiorica, F. Cartei, M. Enea et al., “The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data,” Cancer Treatment Reviews, vol. 33, no. 8, pp. 729–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Valentini, F. Cellini, B. D. Minsky et al., “Survival after radiotherapy in gastric cancer: systematic review and meta-analysis,” Radiotherapy and Oncology, vol. 92, no. 2, pp. 176–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. L. Dikken, E. P. M. Jansen, A. Cats et al., “Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2430–2436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. K. Enestvedt, B. S. Diggs, D. K. Shipley, C. R. Thomas Jr., and K. G. Billingsley, “A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?” Gastrointestinal Cancer Research, vol. 3, no. 6, pp. 233–238, 2009. View at Google Scholar · View at Scopus
  44. S. R. Smalley, L. Gunderson, J. Tepper et al., “Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation,” International Journal of Radiation Oncology Biology Physics, vol. 52, no. 2, pp. 283–293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. M. D'Angelica, M. Gonen, M. F. Brennan, A. D. Turnbull, M. Bains, and M. S. Karpeh, “Patterns of initial recurrence in completely resected gastric adenocarcinoma,” Annals of Surgery, vol. 240, no. 5, pp. 808–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Bozzetti, E. Marubini, G. Bonfanti, R. Miceli, C. Piano, and L. Gennari, “Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group,” Annals of Surgery, vol. 230, no. 2, pp. 170–178, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Bajetta, R. Buzzoni, L. Mariani et al., “Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian trials in medical oncology (ITMO) group,” Annals of Oncology, vol. 13, no. 2, pp. 299–307, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. L. L. Gunderson, M. D. Callister, D. E. Jaroszewski et al., “Localized gastric or gastroesophageal cancer—chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse,” Gastrointestinal Cancer Research, vol. 3, no. 2, supplement 1, pp. S26–S32, 2009. View at Google Scholar
  49. J. J. Bonenkamp, I. Songun, J. Hermans et al., “Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients,” The Lancet, vol. 345, no. 8952, pp. 742–748, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Sasako, K. Maruyama, T. Kinoshita, J. J. Bonenkamp, C. J. van de Velde, and J. Hermans, “Quality control of surgical technique in a multicenter, prospective, randomized, controlled study on the surgical treatment of gastric cancer,” Japanese Journal of Clinical Oncology, vol. 22, no. 1, pp. 41–48, 1992. View at Google Scholar · View at Scopus
  51. C. S. Robertson, S. C. S. Chung, S. D. S. Woods et al., “A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer,” Annals of Surgery, vol. 220, no. 2, pp. 176–182, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Cuschieri, P. Fayers, J. Fielding et al., “Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial,” The Lancet, vol. 347, no. 9007, pp. 995–999, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. J. J. Bonenkamp, J. Hermans, M. Sasako, and C. J. H. van de Velde, “Extended lymph-node dissection for gastric cancer,” The New England Journal of Medicine, vol. 340, no. 12, pp. 908–914, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Sasako, “Risk factors for surgical treatment in the Dutch gastric cancer trial,” British Journal of Surgery, vol. 84, no. 11, pp. 1567–1571, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Cuschieri, S. Weeden, J. Fielding et al., “Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group,” British Journal of Cancer, vol. 79, no. 9-10, pp. 1522–1530, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Songun, H. Putter, E. M.-K. Kranenbarg, M. Sasako, and C. J. van de Velde, “Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1/D2 trial,” The Lancet Oncology, vol. 11, no. 5, pp. 439–449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. A. M. G. Bunt, P. C. W. Hogendoorn, C. J. H. van de Velde, J. A. Bruijn, and J. Hermans, “Lymph node staging standards in gastric cancer,” Journal of Clinical Oncology, vol. 13, no. 9, pp. 2309–2316, 1995. View at Google Scholar · View at Scopus
  58. G. K. Schwartz, K. Winter, B. D. Minsky et al., “Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114),” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1956–1962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Kollmannsberger, W. Budach, M. Stahl et al., “Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO,” Annals of Oncology, vol. 16, no. 8, pp. 1326–1333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. H. C. Kwon, M. C. Kim, K. H. Kim et al., “Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection,” Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 4, pp. 278–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. Kassam, H. Mackay, C. A. Buckley et al., “Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study,” Current Oncology, vol. 17, no. 4, pp. 34–41, 2010. View at Google Scholar · View at Scopus
  62. O. Bouché, M. Ychou, P. Burtin et al., “Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801),” Annals of Oncology, vol. 16, no. 9, pp. 1488–1497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. U. N. Vaishampayan, E. Ben-Josef, P. A. Philip et al., “A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies,” International Journal of Radiation Oncology Biology Physics, vol. 53, no. 3, pp. 675–679, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Das, R. A. Wolff, J. L. Abbruzzese et al., “Concurrent capecitabine and upper abdominal radiation therapy is well tolerated,” Radiation Oncology, vol. 1, no. 1, article 41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. S. Fuchs, J. E. Tepper, D. Niedzwiecki et al., “Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101,” Journal of Clinical Oncology, vol. 29, supplement, abstract 4003, 2011. View at Google Scholar
  66. M. Stahl, M. K. Walz, M. Stuschke et al., “Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction,” Journal of Clinical Oncology, vol. 27, no. 6, pp. 851–856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. R. C. Fields, V. E. Strong, M. Gönen et al., “Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma,” British Journal of Cancer, vol. 104, no. 12, pp. 1840–1847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. J. A. Díaz-González, J. Rodríguez, J. L. Hernández-Lizoain et al., “Patterns of response after preoperative treatment in gastric cancer,” International Journal of Radiation Oncology Biology Physics, vol. 80, no. 3, pp. 698–704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. J. M. Pepek, J. P. Chino, C. G. Willett et al., “Preoperative chemoradiotherapy for locally advanced gastric cancer,” Radiation Oncology, vol. 8, no. 1, article 6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Lee, D. H. Lim, S. Kim et al., “Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): the final report on the ARTIST trial,” Journal of Clinical Oncology, vol. 32, abstract 4008, 2014. View at Google Scholar
  71. S. H. Park, T. S. Sohn, J. Lee et al., “Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses,” Journal of Clinical Oncology, 2015. View at Publisher · View at Google Scholar
  72. http://clinicaltrials.gov.
  73. F. Lordick, Y.-K. Kang, H.-C. Chung et al., “Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 490–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Waddell, I. Chau, D. Cunningham et al., “Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 481–489, 2013. View at Publisher · View at Google Scholar · View at Scopus